Intellectual disability (ID) is defined as limitations in both mental capacity and adaptive behaviour, and affects 2--3% of the population worldwide. A subset of ID, thought to be 5--10% of ID in males, is caused by mutations on the X chromosome (X-linked intellectual disability; XLID). Improvements in sequencing technologies have enabled the association of numerous genetic variants with ID, but the underlying etiology remains poorly understood, and diagnosis and treatment remain limited. Mutations in *KDM5C* (also known as *JARID1C* and *SMCX*) were first found in XLID patients in 2005 ([@bb0025]). Additional *KDM5C* mutations were subsequently identified and they are now thought to account for 1--4% of X-linked ID. This is a substantial proportion; in comparison, Fragile-X syndrome is the most common cause of XLID and accounts for less than 10%. *KDM5C*-linked ID patients (OMIM [300534](300534){#ir0005}) often display short stature (\~ 60% patients) and aggressive behaviour (\~ 30% patients) in addition to mild to severe ID.

*KDM5C* encodes a histone demethylase specific for histone 3 lysine 4 di- and tri-methylation (H3K4me2/3; [@bb0015]). Histone proteins organize the genome, with DNA wrapping around histone octamers to form the basic unit of chromatin. Post-translational modification of histones influences chromosome compaction and provides binding sites for specific proteins, thereby regulating nuclear processes. Distinct histone modifications correlate with different transcriptional states; the KDM5C target H3K4me3 marks active promoters. Patient *KDM5C* mutations lower protein levels through nonsense-mediated decay or diminished protein stability, and missense mutations reduce demethylase activity ([@bb0005]). This suggests a loss-of-function disease mechanism, but the cellular and molecular changes are not fully understood.

In a recent study, Yang Shi and colleagues illuminated *KDM5C*-linked ID through generating and characterising a *Kdm5c*-knockout mouse ([@bb0020]). Importantly, behavioural tests confirm that the mouse is a good model for the disorder, with *Kdm5c*-knockout mice showing heightened aggression, reduced anxiety, social aversion, and defects in learning and memory. The gross architecture of the brain was unaffected in *Kdm5c*-knockout mice, but abnormal neuronal morphology was noted in specific regions related to aggression (the basolateral amygala; BLA) and learning (BLA and cortex). Dendritic spine density was affected in both of these regions, whilst dendritic arborisation was reduced in the BLA ([Fig. 1](#f0005){ref-type="fig"}). Defects in dendritic branching and spine morphology have been identified in human post-mortem samples of different neurological disorders ([@bb0035]), suggesting that these deficits may be a morphological correlate of *KDM5C*-linked ID.

To understand how loss of a histone demethylase results in the cellular defects observed, the authors examined genome-wide changes in gene expression in *Kdm5c*-knockout amygdala and cortex ([@bb0020]). Multiple pathways were misregulated, including pathways important for neurological development and function. Exploration of the contribution of each altered gene/pathway to the behavioural phenotypes should provide insight into potential therapeutic targets for patients. Interestingly, in addition to influencing transcription, KDM5C has been shown to regulate DNA replication ([@bb0050]). Although neurons are post-mitotic, this could have important implications during development, when ID is thought to arise.

To explore the mechanisms of Kdm5c transcriptional regulation, Iwase et al. used primary neuronal cultures from wildtype and *Kdm5c*-KO littermates ([@bb0020]). Kdm5c binding sites across the genome were enriched for CpG islands and high levels of H3K4me3. This finding is consistent with a recent study showing that *Drosophila* Lid, the Kdm5 family ortholog, recognises H3K4me2/3 through its PHD (plant homeodomain) finger, and co-localises with the mark genome-wide ([@bb0040]). Intriguingly, only the Kdm5c-bound genes with the lowest expression levels show significant expression changes in *Kdm5c*-knockout neurons ([@bb0020]). Chromatin modifiers are often postulated to 'fine-tune' expression, and this may explain why robustly transcribed genes show little alteration following its removal. Genes with altered expression levels in *Kdm5c*-knockout neurons predominantly show up-regulation and enhanced H3K4me3, in keeping with Kdm5c acting as a repressor through removal of an active chromatin modification ([Fig. 1](#f0005){ref-type="fig"}). A previous study of *Kdm5c*-knockout embryonic stem cells similarly found that Kdm5c acts at promoters to repress genes, but also suggested that Kdm5c is able to activate genes through the same demethylase activity at enhancers ([@bb0045]). It remains to be seen whether enhancer regulation contributes to *KDM5C* patient symptoms; down-regulated genes were identified in *Kdm5c*-knockout brain and cultured neurons ([@bb0020]) but the mechanisms were not examined.

One intriguing facet of *KDM5C*-linked XLID is that whilst the mutations are germline and therefore present in all cells, the most prominent symptoms are neurological. Changes in gene expression ([@bb0030]) have also been were identified in blood samples from patients with *KDM5C* mutations ([@bb0030]). This suggests that changes in chromatin modification may occur in many tissues without eliciting a phenotype, whereas the highly complex and more recently evolved central nervous system is susceptible. This observation is by no means unique to *KDM5C* mutations; germline mutations in many chromatin modifiers give rise to disorders with a neurological component. Of note, chromatin changes in more easily accessible tissues may be useful as molecular markers for diagnosis and treatment. This is exemplified in a recent study of Sotos Syndrome, a syndromic ID disorder caused by mutations in the histone methyltransferase NSD1, which determined a signature of DNA methylation in peripheral blood that could be used to diagnose sufferers ([@bb0010]).

Mutations in genes encoding chromatin regulators are increasingly being recognized as an important contributor to neurological disorders including ID, autism spectrum disorders and schizophrenia. Furthermore, changes to chromatin can also be instigated by the environment and may contribute to disease susceptibility and prognosis. Thus, chromatin modifications should be considered as promising biomarkers and potential therapeutic targets. Good mouse models, such as the *Kdm5c*-knockout mice described here ([@bb0020]), provide valuable tools to advance clinical practice.

![Model for how mutations in chromatin regulator genes cause disease, exemplified by *KDM5C* mutations. Mutations in chromatin regulator genes affect protein level or activity, such as reduced histone demethylase (HDM) activity of mutant KDM5C. This results in alterations in chromatin conformation at target genes, such as increased H3K4me3 at KDM5C target promoters. Resultant changes in transcription induce cellular phenotypes, to which neurons seem particularly susceptible, leading to disease symptoms.](gr1){#f0005}
